Trial Profile
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Navepegritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms ACcomplisH
- Sponsors Ascendis Pharma
- 20 Dec 2023 According to an Ascendis Pharma media release, further details of the results will be shared early next year.
- 20 Dec 2023 Results published in an Ascendis Pharma Media Release.
- 12 Sep 2023 Pharmacokinetic Endpoints are added, thus making "PK" a trial focus.